NGN Capital
VC Fund
New York, United States
NGN Capital is a venture capital firm specializing in investments in the US and European healthcare sector. The fund focuses specifically on investments in the healthcare, pharmaceutical, and biotech sectors including drug products, medical devices, diagnostics, and healthcare services.
- Total investments:
- 24
- Last investment:
- Lead investor:
- 42%
Last updated:
For AI agents: llms.txt
Industries NGN Capital invests in
Health CareBiotechnologyMedical DevicePharmaceuticalTherapeutics
Stages NGN Capital invests in
Series CSeries BSeries ASeries DSeries F
Countries NGN Capital invests in
United StatesSwitzerlandIsraelGermany
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Noah J. Kroloff
|
|||
Bernard Peperstraete
|
|||
Ivica Cerina
|
|||
Kenneth J. Gorelick
|
|||
Kenneth S. Abramowitz
|
|||
| See all 9 contacts → | |||
Investment Focus
Industry
- Health Care 7 (29%)
- Biotechnology 7 (29%)
- Medical Device 4 (17%)
- Pharmaceutical 4 (17%)
- Therapeutics 3 (13%)
Stage
- Series C 7 (29%)
- Series B 5 (21%)
- Series A 2 (8%)
- Series D 2 (8%)
- Series F 1 (4%)
Country
- United States 7 (29%)
- Switzerland 2 (8%)
- Israel 1 (4%)
- Germany 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Noah J. Kroloff
Partner
|
Partner | Total investments: 1 | Find email | |
|
Bernard Peperstraete
Partner
|
Partner | Total investments: 0 | Find email | |
|
Ivica Cerina
Partner
|
Partner | Total investments: 0 | Find email | |
|
Kenneth J. Gorelick
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
|
Kenneth S. Abramowitz
Co-Founder & General Partner
|
Co-Founder & General Partner | Total investments: 2 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Exosome Diagnostics
|
Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technologymakes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases. | $30M / Series C / Jul 24, 2017 | |
|
Exosome Diagnostics
|
Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technologymakes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases. | $16M / Series B / Jan 07, 2016 | |
|
Exosome Diagnostics
|
Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technologymakes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases. | $17.6M / Series B / Sep 02, 2015 | |
|
Exosome Diagnostics
|
Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technologymakes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases. | $27M / Series B / Mar 11, 2014 | |
Endosense
|
Endosense is a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. Granted the CE mark in May 2009, Endosense's TactiCath® is the first and only force-sensing ablation catheter to give physicians a real-time, objective measure of contact forceduring the catheter ablation procedure. It has undergone considerable pre-clinical and clinical testing, the results of which have created a solid foundation of evidence supporting the feasibility, safety and value of contact force sensing during catheter ablation. | $43.6M / Series C / Nov 27, 2013 | |
|
Endosense
|
Endosense is a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. Granted the CE mark in May 2009, Endosense's TactiCath® is the first and only force-sensing ablation catheter to give physicians a real-time, objective measure of contact forceduring the catheter ablation procedure. It has undergone considerable pre-clinical and clinical testing, the results of which have created a solid foundation of evidence supporting the feasibility, safety and value of contact force sensing during catheter ablation. | $40.3M / Series C / Nov 27, 2012 | |
Small Bone Innovations
|
Small Bones Innovations (SBi) makes devices for small bones and joints, particularly focusing on trauma and arthroplasty. | $15M / Series F / Dec 17, 2010 | |
Artisan Pharma
|
Artisan Pharma, Inc., a biopharmaceutical company, provides critical-care and hospital-based therapeutics to patients, treating physicians, and payors in the United States and internationally. It offers ART-123, a novel, recombinant, and soluble thrombomodulin for the treatment of disseminated intravascular coagulation in sepsis. The company offersits products in Japan, China, Taiwan, and Korea. It has a strategic manufacturing alliance with A-Bio Pharma Pte Ltd. Artisan Pharma, Inc. was formerly known as Artisan Therapeutics, Inc. and changed its name to Artisan Pharma, Inc. in September 2006. The company was founded in 2006 and is headquartered in Waltham, Massachusetts. | $3M / Series C / Jul 20, 2010 | |
|
Exosome Diagnostics
|
Exosome Diagnostics is developing biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are shed into all biofluids, including blood, urine and cerebrospinal fluid, forming a highly enriched source of intact, disease-specific nucleic acids. The Company's proprietary exosome technologymakes use of this natural enrichment to achieve high sensitivity and specificity for rare gene transcripts and the expression of genes responsible for cancers and other diseases. | $20M / Series A / May 11, 2010 | |
|
Artisan Pharma
|
Artisan Pharma, Inc., a biopharmaceutical company, provides critical-care and hospital-based therapeutics to patients, treating physicians, and payors in the United States and internationally. It offers ART-123, a novel, recombinant, and soluble thrombomodulin for the treatment of disseminated intravascular coagulation in sepsis. The company offersits products in Japan, China, Taiwan, and Korea. It has a strategic manufacturing alliance with A-Bio Pharma Pte Ltd. Artisan Pharma, Inc. was formerly known as Artisan Therapeutics, Inc. and changed its name to Artisan Pharma, Inc. in September 2006. The company was founded in 2006 and is headquartered in Waltham, Massachusetts. | $22M / Series B / Mar 01, 2010 | |
| See all 24 investments → | |||
Co-Investors
3i Group
6 deals together
Forbion Capital Partners
5 deals together
Gimv
4 deals together
EDBI
3 deals together
Neomed Management
3 deals together
Viscogliosi Brothers
3 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Device Investors
11,047 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical Device VC Funds
9,894 investors
Health Care Investors in United States
21,541 investors
FAQ
What does NGN Capital invest in?
NGN Capital invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series C and Series B stage. Most of the 24 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact NGN Capital?
Public channels for NGN Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at NGN Capital?
The team at NGN Capital includes Noah J. Kroloff (Partner), Bernard Peperstraete (Partner) and Ivica Cerina (Partner), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
